Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations

Article Gastroenterology & Hepatology

Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease

Stefan Schreiber et al.

Summary: This study demonstrated the pharmacokinetic noninferiority of CT-P13 SC to CT-P13 IV, with comparable clinical remission rates between the two formulations.

GASTROENTEROLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Patients with inflammatory bowel disease (IBD) prefer oral tablets over other modes of medicine administration

Deepa Denesh et al.

Summary: Most patients with inflammatory bowel disease prefer oral tablets over other forms of medication administration. Patients who have experience with biological agents are more accepting of subcutaneous and intravenous forms of medication.

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative

Ajay M Verma et al.

Lancet Gastroenterology & Hepatology (2021)

Add to Collection

Article Gastroenterology & Hepatology

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

Nicholas A. Kennedy et al.

Summary: Infliximab treatment in patients with inflammatory bowel disease results in attenuated serological responses to a single dose of the SARS-CoV-2 vaccine. Delayed second dosing should be avoided in these patients, as vaccination after SARS-CoV-2 infection or a second dose leads to seroconversion in most individuals.

GUT (2021)

Add to Collection

Article Gastroenterology & Hepatology